Sir, Worldwide, antimicrobial resistance among the Grampositive cocci is increasing. In South East Asia, multidrug resistance among Staphylococcus aureus and Streptococcus pneumoniae is particularly problematic. At present, vancomycin-resistant enterococci (VRE) are uncommon in this region, but clusters have been reported. 1 Our previous study and those of others showed that susceptibility of drug-resistant Gram-positive cocci to new antimicrobial agents, even in the pre-marketing stage in South East Asia can differ from those in the Western hemisphere.
2,3 The present study was therefore conducted to examine the in vitro antibacterial activities of linezolid against recent clinical isolates of enterococcus, S. aureus and S. pneumoniae collected from all over Hong Kong.
Isolates of S. aureus and S. pneumoniae were recovered from clinical specimens of in-patients in the participating laboratories (A to E) between 1 January 2000 and 31 March 2001. These laboratories provide a microbiology service to hospitals serving about half of the population in Hong Kong. All isolates were selected at random and were believed to be clinically significant, using local criteria. Only one isolate from each patient was included. The specimen source of the S. pneumoniae isolates was either respiratory tract (n ϭ 117) or blood (n ϭ 3). The numbers of S. pneumoniae isolates from each laboratory were: The Etest (AB Biodisk, Solna, Sweden) was used to determine the MIC of the antimicrobial agents. The following antimicrobial agents were used: cefotaxime, clindamycin, erythromycin, fusidic acid, levofloxacin, linezolid, penicillin, trimethoprim-sulfamethazole and vancomycin. S. aureus susceptibility to methicillin was determined by the oxacillin-salt agar screening test. 4 All the MIC results were interpreted according to NCCLS criteria. 4 For linezolid, the following tentative breakpoints were used: enterococcus (р2 mg/L, susceptible; 4 mg/L, intermediate; Ͼ8 mg/L, resistant); S. pneumoniae (р2 mg/L, susceptible) and S. aureus (р4 mg/L, susceptible).
The Table shows In agreement with other studies, 5 we demonstrated that the penicillin non-susceptible S. pneumoniae, methicillinresistant S. aureus and VRE isolates are inhibited by low concentrations of linezolid. Importantly, activity of linezolid was the same against isolates susceptible or resistant to levofloxacin. This finding is encouraging given that fluoroquinolone-resistant S. pneumoniae are often multiply resistant to penicillin and other antimicrobial agents.
3 In South East Asia, drug-resistant S. pneumoniae is highly prevalent. 6 The in vitro activity of linezolid indicates that it might be a potentially useful drug for therapy of drugresistant S. pneumoniae. However, available clinical data on the role of linezolid in drug-resistant S. pneumoniae are limited. For S. pneumoniae infection, the drug is currently only licensed for therapy of infections caused by penicillinsusceptible strains. Similar to a recent study from Taiwan, drug-resistant Gram-positive bacteria such as fluoroquinolone-resistant S. pneumoniae, but close monitoring of the susceptibility of vancomycin-resistant E. faecium to this agent will be needed. 
